Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density

J Psychiatr Ment Health Nurs. 2009 Nov;16(9):838-42. doi: 10.1111/j.1365-2850.2009.01472.x.


Schizophrenia affects about 1% of the world's population. Those with schizophrenia are at elevated risk of a variety of physical health conditions, including diabetes, coronary heart disease, hypertension and osteoporosis. Osteoporosis secondary to antipsychotic-induced hyperprolactinaemia (i.e. raised prolactin levels) has received little attention, when compared with reports on metabolic syndrome for instance. A recent study established that schizophrenia and prolactin-raising antipsychotic medication is directly associated with hip fractures. This is important and concerning as osteoporotic fractures are associated with much morbidity and mortality. This paper reviews the literature on antipsychotic-induced hyperprolactinaemia and its subsequent effects on bone mineral density.

MeSH terms

  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Bone Density / physiology*
  • Fractures, Bone / etiology
  • Humans
  • Hyperprolactinemia / chemically induced*
  • Hyperprolactinemia / complications
  • Hyperprolactinemia / psychology
  • Osteoporosis / etiology
  • Osteoporosis / pathology
  • Osteoporosis / psychology
  • Risk Factors
  • Schizophrenia / drug therapy*
  • Schizophrenia / physiopathology
  • Schizophrenic Psychology


  • Antipsychotic Agents